| Related Articles |
Impact of body mass index on survival outcome in patients with differentiated thyroid cancer.
Braz J Otorhinolaryngol. 2017 Feb 28;:
Authors: Al-Ammar Y, Al-Mansour B, Al-Rashood O, Tunio MA, Islam T, Al-Asiri M, Al-Qahtani KH
Abstract
INTRODUCTION: Increased body mass index (BMI) is known to be associated with the high prevalence of Differentiated Thyroid Cancers (DTC); however data on its impact on survival outcome after thyroidectomy and adjuvant therapy is scanty.
OBJECTIVE: We aimed to evaluate the impact of BMI on overall survival (OS) and disease free survival (DFS) rates in patients with DTC.
METHODS: Between 2000 and 2011, 209 patients with DTC (papillary, follicular, hurthle cell) were treated with thyroidectomy followed by adjuvant radioactive iodine-131 (RAI) therapy and thyroid-stimulating hormone (TSH) suppression. Based on BMI, patients were divided into five groups; (a) <18.5kg/m(2) (underweight); (b) 18.5-25kg/m(2) (normal weight); (c) 26-30kg/m(2) (overweight); (d) 31-40kg/m(2) (obese) and (e) >40kg/m(2) (morbid obese). Various demographic, clinical and treatment characteristics and related toxicity and outcomes (OS, and DFS) were analyzed and compared.
RESULTS: Median follow up period was 5.2years (0.6-10). Mean BMI was 31.3kg/m(2) (17-72); BMI 31-40kg/m(2) was predominant (89 patients, 42.6%) followed by 26-30kg/m(2) seen in 58 patients (27.8%). A total of 18 locoregional recurrences (8.6%) and 12 distant metastasis (5.7%) were seen. The 10 year DFS and OS rates were 83.1% and 58.0% respectively. No significant impact of BMI on OS or DFS rates was found (p=0.081). Similarly, multivariate analysis showed that BMI was not an independent prognostic factor for OS and DFS.
CONCLUSION: Although BMI can increase the risk of thyroid cancer, it has no impact on treatment outcome; however, further trials are warranted.
PMID: 28325623 [PubMed - as supplied by publisher]
http://ift.tt/2nG3E5Y
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου